Compass Therapeutics (NASDAQ:CMPX) CAO Buys 20,000 Shares of Stock

Compass Therapeutics, Inc. (NASDAQ:CMPX) CAO Neil Lerner acquired 20,000 shares of the company’s stock in a transaction on Thursday, October 1st. The shares were bought at an average cost of $0.92 per share, with a total value of $18,400.00. Following the acquisition, the chief accounting officer directly owned 420,000 shares in the company, valued at approximately $386,400. The trade was a 5.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Neil Lerner also recently made the following trade(s):

• On Thursday, September 24th, Neil Lerner purchased 2,500 shares of Compass Therapeutics stock. The shares were purchased at an average price of $1.14 per share, with a total value of $2,850.00.

Compass Therapeutics Stock Performance

CMPX stock opened at $0.90 on Friday. The firm has a fifty day moving average price of $2.00 and a 200 day moving average price of $2.74. Compass Therapeutics, Inc. has a fifty-two week low of $0.90 and a fifty-two week high of $6.88. The firm has a market cap of $162.28 million, a PE ratio of -2.25 and a beta of 1.02.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, equities analysts predict that Compass Therapeutics, Inc. will post -0.47 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Therapeutics in a report on Friday, July 17th. Lifesci Capital lowered Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 22nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Compass Therapeutics in a report on Wednesday, September 23rd. Piper Sandler upped their price target on shares of Compass Therapeutics from $4.00 to $6.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Finally, Wall Street Zen downgraded shares of Compass Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Compass Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $10.21.

Institutional Trading of Compass Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. purchased a new stake in Compass Therapeutics during the 2nd quarter worth approximately $24,707,000. BVF Inc. IL raised its holdings in shares of Compass Therapeutics by 63.5% during the 4th quarter. BVF Inc. IL now owns 7,764,842 shares of the company’s stock worth $41,697,000 after acquiring an additional 3,014,842 shares during the period. Palo Alto Investors LP purchased a new position in Compass Therapeutics during the second quarter worth about $12,771,670. Sofinnova Investments Inc. lifted its holdings in Compass Therapeutics by 65.9% in the fourth quarter. Sofinnova Investments Inc. now owns 3,365,446 shares of the company’s stock valued at $18,072,000 after acquiring an additional 1,336,560 shares during the last quarter. Finally, NEXTBio Capital Management LP acquired a new position in shares of Compass Therapeutics in the 4th quarter valued at $5,982,000. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines designed to activate and direct the immune system against cancer and other serious diseases. The company’s research is centered on immuno-oncology, with the goal of creating therapies that can stimulate antitumor immune responses and improve outcomes for patients.

Compass Therapeutics has developed a pipeline of proprietary antibody therapeutics, including CTX-471, an investigational monoclonal antibody intended to activate CD137, an immune-stimulatory receptor found on certain immune cells.